Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05008055 · ClinicalTrials.gov registry record · Phase 2
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05008055 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT05008055, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
Interventions
- DRUG Capivasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05008055
The ClinicalTrials.gov registry entry for NCT05008055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capivasertib is the first listed.
NCT05008055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05008055 about?
NCT05008055 is a clinical study titled "Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma". This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
What is the current status of trial NCT05008055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-11-03. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT05008055?
The interventions under investigation include: Capivasertib (DRUG).
Who is sponsoring clinical trial NCT05008055?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.